Baidu
map

PNAS:慢性应激产生老年痴呆症相关的蛋白质聚集体

2012-04-10 mumu 生物谷

在3月26日网络版Proceedings of the National Academy of Sciences发表的文章中,加利福尼亚大学圣地亚哥医学院的研究人员指出,反复应激触发小鼠脑细胞内不溶性tau蛋白聚集体的生产和堆积。 聚合体类似于神经纤维缠结(NFTs),一种修改的蛋白质结构,是阿尔茨海默病的一种生理标志。该发现至少部分解释了临床研究为什么发现容易紧张的人与散发型阿尔茨海默氏病(A

在3月26日网络版Proceedings of the National Academy of Sciences发表的文章中,加利福尼亚大学圣地亚哥医学院的研究人员指出,反复应激触发小鼠脑细胞内不溶性tau蛋白聚集体的生产和堆积。

聚合体类似于神经纤维缠结(NFTs),一种修改的蛋白质结构,是阿尔茨海默病的一种生理标志。该发现至少部分解释了临床研究为什么发现容易紧张的人与散发型阿尔茨海默氏病(AD)发生之间的密切联系,其中散发型阿尔茨海默氏病占所有老年痴呆症病例的95%。

在小鼠模型中,研究人员发现,日常生活中可能经历的反复的情感应激事件导致神经元中tau蛋白质的磷酸化和可溶性改变,而这些事件对于阿尔茨海默氏病NFT病理学的发展是至关重要的。该作用在与记忆形成、组织和贮存相关的海马中最显著。在AD患者中,海马是典型的第一个受tau病理和大量细胞死亡与收缩重击影响的大脑区域。并不是所有形式的紧张都具有相同的威胁作用。既往研究指出,急性应激(单一的一过性事件)不会导致磷化tau蛋白累积上的持久性、逐渐减弱的长期变化。总体上,急性应激诱导的细胞改变是暂时的,可能是有益的。

急性应激可能对大脑可塑性有用,有助于易化学习。慢性应激和应激通路的连续激活可能导致形成应激回路的病理改变。人随着年龄增加,他们的神经回路也许激活得太多以致变得不再强健,也许不能从应激效应中完全复原。

研究发现,应激影响两个关键的促皮质释放素受体,意味着它们很可能是潜在治疗方法的靶标。我们不能排除应激,必需能对应激刺激有不同水平的反应。但可以用拮抗分子减少神经元的应激效应。应激系统还能反应,但是可调低大脑和海马的反应,以便不形成有害的永久性损伤。(生物谷bioon.com)

doi:10.1073/pnas.1203140109
PMC:
PMID:

Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation

Robert A. Rissman, Michael A. Staup, Allyson Roe Lee, Nicholas J. Justice, Kenner C. Rice, Wylie Vale, and Paul E. Sawchenko

Exposure and/or sensitivity to stress have been implicated as conferring risk for development of Alzheimer's disease (AD). Although the basis for such a link remains unclear, we previously reported differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 in acute stress-induced tau phosphorylation (tau-P) and solubility in the hippocampus. Here we examined the role of CRFRs in tau-P induced by repeated stress and the structural manifestations of altered tau solubility. Robust tau-P responses were seen in WT and CRFR2 null mice exposed to repeated stress, which were sustained at even 24 h after the final stress exposure. A portion of phosphorylated tau in these mice was sequestered in detergent-soluble cellular fractions. In contrast, CRFR1 and CRFR double-KO mice did not exhibit repeated stress-induced alterations in tau-P or solubility. Similarly, treatment with CRFR1 antagonist attenuated repeated stress-induced tau-P. Using histochemical approaches in a transgenic CRFR1 reporter mouse line, we found substantial overlap between hippocampal CRFR1 expression and cells positive for phosphorylated tau after exposure to repeated stress. Ultrastructural analysis of negatively stained extracts from WT and CRFR2 null mice identified globular aggregates that displayed positive immunogold labeling for tau-P, as well as conformational changes in tau (MC1) seen in early AD. Given that repeated stress exposure results in chronic increases in hippocampal tau-P and its sequestration in an insoluble (and potentially prepathogenic) form, our data may define a link between stress and an AD-related pathogenic mechanism.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2013-02-10 Boyinsh
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-06-29 drwjr
  5. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2037043, encodeId=d356203e04340, content=<a href='/topic/show?id=da2653514ab' target=_blank style='color:#2F92EE;'>#慢性应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53514, encryptionId=da2653514ab, topicName=慢性应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f1477, createdName=s_pl2008, createdTime=Thu Feb 14 12:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836058, encodeId=4c711836058e0, content=<a href='/topic/show?id=4613e1212fc' target=_blank style='color:#2F92EE;'>#痴呆症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71212, encryptionId=4613e1212fc, topicName=痴呆症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Sun Feb 10 16:30:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765468, encodeId=0bb81e654681d, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Sep 20 11:30:00 CST 2012, time=2012-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855248, encodeId=35af18552489a, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Fri Jun 29 16:30:00 CST 2012, time=2012-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296846, encodeId=0ac41296846c8, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445068, encodeId=de811445068c4, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Thu Apr 12 12:30:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]

相关资讯

Nat Neurosci:研究发现秀丽隐杆线虫应对氧浓度行为调节机制

《Nature Neuroscience》3月4日在线发表英国剑桥大学的研究人员的研究报告,该报告报道了秀丽隐杆线虫应对环境中氧浓度变化的行为调节机制。这项研究帮助我们在了解动物的持续防御行为方面迈出重要的一步。 对所有生物而言,每时每刻都有一大堆的环境信息需要应对,因此其感知系统会进化产生相应的适应机制以对大多数环境刺激作出快速反应或忽略某些刺激。一些有害刺激能在很长时间内被生物所记住,但是,

Neuropsychopharmacol:兴奋剂效果“因鼠而异”

加拿大不列颠哥伦比亚大学研究人员3月28日在美国《神经精神药理学》杂志上发表报告称,他们以实验鼠为对象进行了一项刺激类药物测试。在实验中,老鼠可以选择“容易任务”或“困难任务”,选择“困难任务”并且成功通过的老鼠会得到加倍的奖励。研究人员发现,有一些老鼠选择“困难任务”的次数明显多于他们的“懒惰”同伴,研究人员将它们定义为“自我驱动强烈”的老鼠。 之后,研究人员给这两类老鼠都注射刺激类药物安非他

PNAS:干细胞研究新进展或可加快治疗运动神经元疾病

来自英国爱丁堡大学、伦敦大学国王学院、美国哥伦比亚大学和旧金山大学的科学家们利用前沿干细胞研究方法取得一项研究突破,从而可能会加快人们开发出治疗运动神经元疾病(motor neurone disease, MND)的新方法。 中国细胞生物学学会干细胞生物学分会2012年春季会议 他们从一名患有遗传性MND疾病的病人身上提取皮肤细胞,并利用提取到的皮肤细胞构建出运动神经元。 他们证实在90%以

J. Neurosci.:美揭示控制体重和能量的细胞机理

近日,据美国物理学家组织网报道,美国耶鲁大学科学家发现了一种关键细胞机理,能帮大脑控制我们每天的食物摄入量、体重以及干活时能不能精力充沛。相关论文发表在《神经科学杂志》(The Journal of Neuroscience)上。 下丘脑部位的神经元调节着体温、摄食等基本机能,维持着身体的能量平衡,它们发出的轴突遍布于整个神经系统。这里有两种功能相反的神经元,一种是黑色素浓集激素(MCH)神经元

Nat. Transl. Psychiat.:发现自闭症生物标记物

补体蛋白C3(C3b/A/1)的晶体结构图,以及C3f结构域(用方框表示)所处的位置。 到目前为止,科学家还没有发现获得公认的自闭症生物标记物。来自瑞典乌普萨拉大学Berzelii中心和生命科学实验室的研究人员与来自瑞典林奈大学和伊朗德黑兰大学医学院的同事们发现一些大有希望的自闭症生物标记物。 很多疾病是由人体细胞内部和外部的蛋白变化而导致的。通过研究组织和体液的蛋白谱(protein pat

PNAS:神经mRNAs的传输方式

根据Sanjay Tyagi博士和新泽西医学和牙科大学的同事们的研究表明:蛋白前体对脊椎延伸中神经信号的单一传输是必需的。 这项研究最近发表在PNAS杂志上。 轴突尖端和神经元的突触信号传输过程中涉及的蛋白质以前体形式(信使RNA或mRNA)传输。新泽西医学院医学系、公共健康研究所Tyagi副教授解释说:位于突触的基因被翻译[成蛋白质]是必需。Tyagi补充说:如果该部位需要一种蛋白质的多个副

Baidu
map
Baidu
map
Baidu
map